Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation
- PMID: 8554610
- DOI: 10.1006/bbrc.1995.2852
Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation
Abstract
Activation of the classical complement pathway has been proposed as a mechanism of neurodegeneration in Alzheimer's disease. This activation is a result of the binding of C1q to amyloid beta-peptide (A beta). Recent work has shown that A beta/C1q binding has an additional consequence: enhanced formation of the neurotoxic, fibrillar, cross beta-pleated A beta configuration. Here we show that C1q enhances A beta aggregation at physiologically relevant, nanomolar concentrations of the peptides, and demonstrate that the kinetics of this enhancement are consistent with a nucleating interaction. We also show that the intact, multimeric structure of C1q, which offers multiple A beta binding sites spaced at 2-3 nm intervals, is required.
Similar articles
-
beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain.J Immunol. 1994 May 15;152(10):5050-9. J Immunol. 1994. PMID: 8176223
-
Localization and cell association of C1q in Alzheimer's disease brain.Exp Neurol. 1996 Mar;138(1):22-32. doi: 10.1006/exnr.1996.0043. Exp Neurol. 1996. PMID: 8593893
-
Complement C1q does not bind monomeric beta-amyloid.Exp Neurol. 1994 Jul;128(1):136-42. doi: 10.1006/exnr.1994.1121. Exp Neurol. 1994. PMID: 8070518
-
[Oxidative stress, beta-amyloide peptide and Alzheimer's disease].Gac Med Mex. 2006 May-Jun;142(3):229-38. Gac Med Mex. 2006. PMID: 16875352 Review. Spanish.
-
Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide.Neurobiol Aging. 2004 May-Jun;25(5):563-8. doi: 10.1016/j.neurobiolaging.2003.12.027. Neurobiol Aging. 2004. PMID: 15172731 Review.
Cited by
-
Age-Dependent Hippocampal Proteomics in the APP/PS1 Alzheimer Mouse Model: A Comparative Analysis with Classical SWATH/DIA and directDIA Approaches.Cells. 2021 Jun 24;10(7):1588. doi: 10.3390/cells10071588. Cells. 2021. PMID: 34202490 Free PMC article.
-
Structural and functional anatomy of the globular domain of complement protein C1q.Immunol Lett. 2004 Sep;95(2):113-28. doi: 10.1016/j.imlet.2004.06.015. Immunol Lett. 2004. PMID: 15388251 Free PMC article. Review.
-
Using animal models to determine the significance of complement activation in Alzheimer's disease.J Neuroinflammation. 2004 Oct 12;1(1):18. doi: 10.1186/1742-2094-1-18. J Neuroinflammation. 2004. PMID: 15479474 Free PMC article.
-
Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.Am J Pathol. 2000 Feb;156(2):489-99. doi: 10.1016/S0002-9440(10)64753-0. Am J Pathol. 2000. PMID: 10666378 Free PMC article.
-
The effect of insomnia on development of Alzheimer's disease.J Neuroinflammation. 2020 Oct 6;17(1):289. doi: 10.1186/s12974-020-01960-9. J Neuroinflammation. 2020. PMID: 33023629 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources